Tag: offer

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

LOS ANGELES, July 23, 2025 /PRNewswire/ -- Viewers of Public Television are in for an enlightening experience as "Empowered with Meg Ryan" presents a...

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billionRecorded Q2'25 consolidated operating profit of KRW 475.6 billionSolid momentum sustained through capacity ramp-up and stable project...

Leverages AI to offer real-time support, raise service requests, and simplify complex transaction queries MUMBAI, India, July 23, 2025 /PRNewswire/ -- Axis Trustee Services Limited (ATSL),...

DHAKA, Bangladesh, July 23, 2025 /PRNewswire/ -- Himel, the globally acclaimed manufacturer and supplier of electric products, has officially launched in Bangladesh, igniting its presence...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

Virtu Financial, LTP, Hidden Road Partners, DV Chain, CoinRoutes, and Amber Group included in partner ecosystem to provide deep liquidity and competitive pricing to institutional...